Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 737 across all filing types
Latest filing 2026-06-08 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice to shareholders of the company’s first extraordinary general meeting (临时股东会), outlining meeting purpose, time, venue, voting methods and proxy forms (附件一、附件二、附件三). This is not the actual minutes or results, nor a financial report, but materials soliciting shareholder votes and providing proxy information. Therefore it falls under Proxy Solicitation & Information Statement (PSI).
2026-06-08 Chinese
第五届董事会第十三次会议决议公告
Regulatory Filings Classification · 85% confidence The document is a Chinese A-share announcement of the board of directors’ 13th meeting resolutions, including vote counts and decisions to convene an EGM. It does not contain financial statements, earnings information, proxy materials, or a report publication notice, nor does it describe changes in management. It is a general regulatory disclosure of board meeting resolutions, so the most appropriate category is Regulatory Filings (RNS).
2026-06-08 Chinese
关于持股5%以上股东减持计划预披露的公告
Regulatory Filings Classification · 74% confidence The document is a formal announcement (“公告”) by the company regarding a planned reduction of shares by a >5% shareholder. It outlines the shareholder’s lock-up commitments, reduction period and quantities, legal references, and risk disclosures, but contains no financial statements or performance data. This is a routine regulatory disclosure of a major shareholder’s share reduction plan rather than a standalone financial report or capital issuance. It falls under general regulatory filings that do not fit a more specific category.
2026-06-04 Chinese
第五届董事会第十二次会议决议公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement of the board of directors’ resolutions regarding the company’s proposal to terminate a simple procedure issuance and implement a new A-share issuance to specific investors, including detailed share issue terms, pricing, quantity, use of proceeds, and related authorizations. This is not a management or board personnel change (MANG), nor an earnings release, but specifically relates to a new share issue and capital change. Accordingly, it falls under Share Issue/Capital Change (Code: SHA).
2026-05-13 Chinese
拓新药业集团股份有限公司截至2025年12月31日止前次募集资金使用情况鉴证报告
Regulatory Filings Classification · 45% confidence The document is a regulatory “募集资金使用情况鉴证报告” and special report on the storing and usage of prior fundraising proceeds, complete with auditor’s assurance and detailed tables on fund destination. It is not an AGM presentation, earnings release, MD&A, or formal financial statement (annual or interim report), nor a share issuance announcement; rather, it is a compliance filing under China Securities Regulatory and exchange rules. It therefore falls into the general ‘Regulatory Filings’ fallback category.
2026-05-13 Chinese
关于2026年度向特定对象发行A股股票摊薄即期回报及采取填补措施和相关主体承诺的公告
Share Issue/Capital Change Classification · 92% confidence The document is an official announcement by a listed company regarding a specific object A-share issuance (定向增发), describing the dilution of immediate returns, remedial measures, commitments by stakeholders, fundraising use, and capital structure impact. This clearly constitutes a new share issue/capital change announcement, matching the Share Issue/Capital Change category.
2026-05-13 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.